A new CHOP study found only one in three eligible patients took Beyfortus when the medication that protects against severe ...

Q2 2025 Management View Paul Hudson, CEO, reported "another strong quarter with double-digit sales growth," attributing the ...

Children's Health FDA approves new drug Beyfortus to protect babies, toddlers from RSV RSV can result in ‘large number’ of emergency department, physician visits, FDA official says ...

Doctors say RSV antibody shot for babies is still challenging to find RSV season is ramping up, and doctors are hoping a new shot to prevent the virus in young children will ease the caseload this ...

The Beyfortus antibody shot, manufactured by drugmakers AstraZeneca and Sanofi, was approved by the Food and Drug Administration in July as a way to prevent RSV in infants and children up to 24 ...

Amid an ongoing shortage of nirsevimab, an RSV immunization for young children, the US Centers for Disease Control and Prevention has announced that more than 77,000 additional doses will be ...

Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs Late-breaking data show infant respiratory syncytial virus (RSV ...

When Beyfortus was approved over the summer, AstraZeneca and Sanofi, the two companies that manufacture the drug, said it would be available for babies in time for RSV season this year.

Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe, and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.

The new shot, which goes by the brand name Beyfortus, slashed infants’ risk of being hospitalized for RSV by 80% in clinical trials. It promised to be a game-changer for the youngest patients.

Beyfortus is supplied as a 50mg/0.5mL and 100mg/mL prefilled syringe. The product is expected to be available for the upcoming 2023-2024 RSV season.

Beyfortus is not known to interact with other medications, herbs, supplements, foods, or alcohol. The manufacturer of Beyfortus didn’t look at interactions in studies of the drug.